Pro-Pointer, Inc. Update: Company Continues Negotiations With International Pharmaceutical Distributors

by Zagros on August 16, 2020

Marketwire “Press Releases “

LAS VEGAS, NV — (MARKET WIRE) — 08/16/10 -
Pro Pointer, Inc. (PINKSHEETS: PPII), through its wholly owned subsidiary, Coenzyme-A Technologies, Inc., is pleased to announce it is continuing the distribution negotiations with ERC Saglik Urunleri, a Mediterranean Company, and also Global Pharmaceuticals, a Middle Eastern and North African Company. Both of these companies are leading international wholesale pharmaceutical distributors for medical-optical devices, pharmaceutical equipment and nutraceutical products and have large customer bases in the Mediterranean region, North Africa and the Middle East territories. ERC Saglik Urunleri is currently serving many of the over 1,100 hospitals, 18,000 independent pharmacies and approximately 22,000 independent medical practices in their respective territories.

Verbal negotiations have indicated that an Opening Order by ERC Saglik Urunleri alone is estimated to be at 500,000 individual units of the “Pure Coenzyme-A” nutraceutical product development. This translates to approx. over $15,000,000.00 in sales alone from this pending business transaction. These two pending agreements could possibly bring the company’s annual earnings from approx. $500,000.00 in 2009 to well over the $30,000,000.00 million mark during the course of 2010.

Related Blogs

Leave a Comment

Previous post:

Next post: